Gene Therapy Stock Faces Class Action as FDA Halts REGENXBIO Trial Over Safety Concerns

REGENXBIO Inc. faces a significant legal challenge following a catastrophic development in its lead gene therapy program. The Portnoy Law Firm has announced a class action lawsuit on behalf of investors who purchased $RGNX securities between February 9, 2022 and January 27, 2026—a four-year window that encompasses both the company's public optimism about its pipeline and the dramatic collapse that followed recent FDA regulatory action.

The lawsuit alleges that REGENXBIO made materially false and misleading statements regarding the safety and efficacy of RGX-111, a potentially blockbuster in-vivo gene therapy candidate. The allegations center on the company's public disclosures during a period when investors were building positions based on the premise that the therapy was progressing safely toward potential commercialization. The legal action represents a watershed moment for the biotechnology sector, where clinical failures in late-stage programs can obliterate shareholder value in a matter of hours.

The Clinical and Regulatory Crisis

On January 28, 2026, REGENXBIO disclosed that the U.S. Food and Drug Administration (FDA) had placed a clinical hold on RGX-111 following a serious adverse event in an ongoing trial. Specifically, an intraventricular central nervous system (CNS) tumor was discovered in a trial participant—a development that immediately raised red flags about the safety profile of the therapy. This represents precisely the kind of severe, unexpected toxicity that can render a promising therapeutic candidate untenable from both a regulatory and commercial standpoint.

The market's reaction was swift and severe:

• $RGNX stock fell nearly 18% on the announcement
• The decline wiped out hundreds of millions in market capitalization
• Trading activity spiked as investors rushed to exit positions
• The stock's performance underscores the binary nature of biotechnology investing

For context, CNS tumors in gene therapy trials represent a particularly concerning safety signal, as they suggest the therapy vector or the therapeutic gene itself may have genotoxic properties. This type of adverse event typically leads regulatory agencies to take a conservative stance, and recovery from such a clinical hold is rarely straightforward—if it occurs at all.

Market Context and Competitive Implications

The RGX-111 clinical hold arrives at a critical juncture for REGENXBIO and the broader gene therapy sector. The company had positioned RGX-111 as a cornerstone asset with significant commercial potential, making its development timeline a key driver of shareholder expectations. The four-year window covered by the class action lawsuit is particularly significant because it includes periods when REGENXBIO was actively promoting its pipeline progress to investors and capital markets.

The gene therapy sector has faced mounting scrutiny over recent years, with several high-profile programs encountering unexpected toxicity signals late in development. This pattern has raised questions about:

• The adequacy of preclinical safety testing in gene therapy programs
• The transparency of companies regarding emerging safety concerns
• The timing and completeness of regulatory disclosures to investors
• The sustainability of valuations based on single-asset pipelines

For competitors in the gene therapy space—companies like REGENXBIO's peers in vector-based therapeutics—this development may intensify regulatory scrutiny and investor skepticism. It also provides a cautionary tale about pipeline concentration risk, where companies with limited therapeutic candidates face existential threats when individual programs encounter problems.

Investor Implications and Forward Outlook

The class action lawsuit carries significant implications for multiple stakeholder groups:

For Current Shareholders: The combination of the 18% stock decline and ongoing regulatory uncertainty creates substantial downside risk. Investors holding $RGNX face an extended period of uncertainty as REGENXBIO works with the FDA to understand the safety signal and determine whether the program can be salvaged.

For Class Action Participants: Investors who purchased shares during the alleged period of misleading statements may pursue recovery, though success is contingent on demonstrating that the company knowingly or recklessly made false statements about RGX-111's safety profile. Securities litigation in the biotech sector has historically been challenging, requiring investors to prove scienter (intent to defraud) or at minimum recklessness.

For the Broader Biotech Sector: This episode underscores the importance of transparency regarding emerging safety data and the risks of market-moving adverse events in clinical development. It may also accelerate investor demand for more frequent and detailed safety updates from gene therapy companies.

Regulatory and Compliance Considerations: The FDA's clinical hold and the subsequent class action create a complex environment for REGENXBIO management. The company must simultaneously engage with regulators on the safety issue while managing disclosure obligations to investors and dealing with litigation defense.

Conclusion: Navigating Uncertainty

REGENXBIO's situation exemplifies the high-stakes nature of biotechnology investing, where promising early-stage candidates can rapidly transform into sources of shareholder loss. The four-year class action window reflects a lengthy period during which investors made capital allocation decisions based on the company's public statements about RGX-111. As the litigation proceeds, key questions will include whether REGENXBIO adequately disclosed emerging safety signals and whether management statements about the program's viability were supported by available evidence at the time they were made.

The company now faces a difficult path forward: working to resolve the clinical hold with regulators while simultaneously addressing shareholder litigation and rebuilding investor confidence. Given the severity of the safety signal and the binary nature of gene therapy program outcomes, $RGNX investors should prepare for an extended period of significant uncertainty.